Jardiance and metformin
Pro Research Analysisby 
Searched over 200M research papers
Jardiance and Metformin: A Comprehensive Overview
Introduction to Jardiance and Metformin for Type 2 Diabetes
Jardiance (Empagliflozin) and Metformin are two prominent medications used in the management of type 2 diabetes. Jardiance, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, and Metformin, a biguanide, work through different mechanisms to control blood glucose levels. This article explores their individual and combined use, efficacy, and safety profiles.
Mechanism of Action
Jardiance (Empagliflozin)
Jardiance works by inhibiting the reabsorption of glucose in the kidneys. Specifically, it targets the SGLT2 proteins in the proximal tubules, leading to increased glucose excretion through urine. This insulin-independent mechanism helps lower blood glucose levels effectively .
Metformin
Metformin primarily works by reducing hepatic glucose production and improving insulin sensitivity. It decreases the amount of glucose absorbed from the intestines and enhances peripheral glucose uptake and utilization.
Efficacy in Glycemic Control
Jardiance Alone and in Combination
Clinical trials have demonstrated that Jardiance, whether used alone or in combination with other antidiabetic medications, significantly improves glycemic control. In phase III trials, Jardiance was shown to reduce glycated hemoglobin (HbA1c) levels, body weight, and systolic blood pressure in adults with type 2 diabetes . When combined with Metformin, Jardiance was found to be noninferior to glimepiride at 52 and 104 weeks and superior at 104 weeks in reducing HbA1c levels .
Metformin
Metformin remains a first-line treatment for type 2 diabetes due to its efficacy in lowering blood glucose levels and its favorable safety profile. It is often used as a monotherapy or in combination with other antidiabetic agents, including SGLT2 inhibitors like Jardiance.
Safety and Tolerability
Jardiance
Jardiance is generally well-tolerated, with most adverse events being mild to moderate. It does not intrinsically increase the risk of hypoglycemia, although the risk is higher when used with insulin or sulfonylureas . The drug has also been approved for use in children aged 10 years and older, expanding its therapeutic reach .
Metformin
Metformin is well-known for its safety and tolerability. Common side effects include gastrointestinal issues, which are usually transient. It is contraindicated in patients with severe renal impairment due to the risk of lactic acidosis.
Recommendations and Guidelines
The National Institute for Health and Care Excellence (NICE) recommends Jardiance as a treatment option for adults with type 2 diabetes when Metformin, sulfonylurea, or pioglitazone are contraindicated or not tolerated . This endorsement highlights the importance of Jardiance as a versatile option in diabetes management.
Conclusion
Jardiance and Metformin are both effective in managing type 2 diabetes, either as monotherapies or in combination. Jardiance offers a novel, insulin-independent mechanism of action, making it a valuable addition to the therapeutic arsenal. Metformin continues to be a cornerstone in diabetes treatment due to its efficacy and safety. Together, they provide a robust approach to achieving optimal glycemic control.
Sources and full results
Most relevant research papers on this topic